SyntaxBio (Chicago, IL) is developing a proprietary CRISPR/Cas9 based, genetic programming platform technology that converts cells into biological computers using DNA based instructions that read like lines of code. SyntaxBio is a genetic platform that can program populations of cells without the need for consistent external intervention.
Investors 1
| Date | Name | Website |
| - | XLerateHea... | xleratehea... |
Mentions in press and media 1
| Date | Title | Description |
| 05.08.2025 | iBIO Releases Inaugural Member Investor Portfolio Report Showcasing $1.24 Billion in Illinois Life Sciences Investment | Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030 CHICAGO, Aug. 5, 2025 /PRNewswire-PRWeb/ -- The Illinois Biotechnology Innovation Organization (iBIO)... |